Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$73.49 USD

73.49
4,870,753

+0.68 (0.93%)

Updated May 14, 2024 04:00 PM ET

After-Market: $73.48 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (142 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Trump Focuses on APAC: 4 MedTech Stocks to Watch

Considering Trump's growing focus on APAC, the region seems to be poised to yield accretive returns over the long term. Favorable MedTech trends in APAC hold promise.

    Boston Scientific's (BSX) Q3 Earnings In Line, Sales Top

    Boston Scientific (BSX) has posted impressive Q3 results by delivering revenue growth across all segments.

      Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

      Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

        MedTech Stock Q3 Earnings Roster for Oct 26: BSX, RMD & More

        Investors are concerned about the Medical sector that saw a lot of struggle during the first nine months of the year, thanks to the political change and the ongoing policy-restructuring related battle.

          EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?

          Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.

            Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?

            Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.

              Boston Scientific Grows on New Products, Currency Woe Ails

              Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.

                Boston Scientific's Apama Deal to Boost Electrophysiology Arm

                Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.

                  Abbott's Ellipse ICD Receives FDA Approval for MRI Scans

                  Abbott's (ABT) Rhythm Management segment to gain traction with the latest FDA approval of Ellipse ICD for MR-conditioning labeling.

                    Boston Scientific's Resonate Devices Boost Cardiac Rhythm Arm

                    Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.

                      Medtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI

                      Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.

                        Boston Scientific MultiSENSE Study on HeartLogic Positive

                        Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.

                          Boston Scientific Grows on Innovation, Buyouts Amid Woes

                          While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.

                            Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm

                            Abbott Laboratories' (ABT) receipt of FDA approval for its Full MagLev HeartMate 3 LVAD strengthens one of its major business segments.

                              Boston Scientific (BSX) Tops Q2 Earnings & Sales, View Up

                              Boston Scientific's (BSX) Q2 results gain on balanced segmental growth. Currency remains a dampener though.

                                Boston Scientific (BSX) Exceeds Q2 Earnings, Sales Estimates

                                Boston Scientific (BSX) rides high on acquisitions and FDA approvals.

                                  Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More

                                  The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.

                                    FDA Approval Widens Medtronic's (MDT) TAVR Platform Reach

                                    Medtronic plc (MDT), a well established player in the medical technology, services and solutions space, recently announced FDA approval for the extended use of its self-expanding CoreValve Evolut transcatheter aortic valve replacement (TAVR) platform.

                                      Medtronic (MDT) Launches Resolute Onyx DES Device in Japan

                                      Medtronic plc (MDT), a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest revenue grossing Cardiovascular segment.

                                        Boston Scientific Rides on New Growth Plans amid Headwinds

                                        On Jun 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

                                          Brian Hamilton headshot

                                          Top Stock Reports for Halliburton, Boston Scientific & Anheuser-Busch

                                          Today's Research Daily features new research reports on 16 major stocks, including Halliburton (HAL), Boston Scientific (BSX), and Anheuser-Busch (BUD).

                                            Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised)

                                            Generally, DBS therapy is a surgical procedure of placing a device that stimulates specific areas in the brain using electrical signals.

                                              Boston Scientific Wins CE Mark for Vercise Gevia DBS System

                                              Boston Scientific Corporation (BSX) recently won CE mark for its Vercise Gevia Deep Brain Stimulation (DBS) System.

                                                Boston Scientific (BSX) Up 4.4% Since Earnings Report: Can It Continue?

                                                Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Boston Scientific Trades Up on Strong Q1 amid Recall Issues

                                                  On May 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).